JP2013256538A - Composition containing n-acyl tryptamine - Google Patents
Composition containing n-acyl tryptamine Download PDFInfo
- Publication number
- JP2013256538A JP2013256538A JP2013202908A JP2013202908A JP2013256538A JP 2013256538 A JP2013256538 A JP 2013256538A JP 2013202908 A JP2013202908 A JP 2013202908A JP 2013202908 A JP2013202908 A JP 2013202908A JP 2013256538 A JP2013256538 A JP 2013256538A
- Authority
- JP
- Japan
- Prior art keywords
- pain
- composition
- formula
- acyltryptamine
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- APJYDQYYACXCRM-UHFFFAOYSA-N Tryptamine Natural products C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 title abstract description 8
- 208000002193 Pain Diseases 0.000 claims abstract description 22
- 208000006820 Arthralgia Diseases 0.000 claims abstract description 19
- 208000008035 Back Pain Diseases 0.000 claims abstract description 19
- 208000034656 Contusions Diseases 0.000 claims abstract description 16
- 208000000112 Myalgia Diseases 0.000 claims abstract description 16
- 208000034526 bruise Diseases 0.000 claims abstract description 15
- 208000008930 Low Back Pain Diseases 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 239000012453 solvate Substances 0.000 claims abstract description 6
- 208000013465 muscle pain Diseases 0.000 claims description 12
- 125000001931 aliphatic group Chemical group 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 3
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Chemical group CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims description 2
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000755 henicosyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001196 nonadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 description 27
- 238000002360 preparation method Methods 0.000 description 26
- 206010052428 Wound Diseases 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 239000006071 cream Substances 0.000 description 12
- 206010019133 Hangover Diseases 0.000 description 9
- 206010000496 acne Diseases 0.000 description 9
- JHKBQGYMCOBVJV-UHFFFAOYSA-N n-[2-(1h-indol-3-yl)ethyl]nonanamide Chemical compound C1=CC=C2C(CCNC(=O)CCCCCCCC)=CNC2=C1 JHKBQGYMCOBVJV-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 229960003987 melatonin Drugs 0.000 description 7
- 244000299461 Theobroma cacao Species 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 229940126585 therapeutic drug Drugs 0.000 description 6
- 235000009470 Theobroma cacao Nutrition 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000037303 wrinkles Effects 0.000 description 5
- 240000007436 Cananga odorata Species 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 210000000707 wrist Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000003779 hair growth Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 241000722951 Annona Species 0.000 description 2
- 244000021317 Annona cherimola Species 0.000 description 2
- 235000002272 Annona cherimola Nutrition 0.000 description 2
- 244000030795 Annona lutescens Species 0.000 description 2
- 235000005288 Annona lutescens Nutrition 0.000 description 2
- 235000007571 Cananga odorata Nutrition 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 210000000085 cashmere Anatomy 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000003811 finger Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 0 *C(NCCc1c[n]c2ccccc12)=O Chemical compound *C(NCCc1c[n]c2ccccc12)=O 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000007755 Annona Nutrition 0.000 description 1
- 235000011518 Annona purpurea Nutrition 0.000 description 1
- 244000028821 Annona squamosa Species 0.000 description 1
- 235000005274 Annona squamosa Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000243321 Cnidaria Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 241001406921 Squamosa Species 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-N disulfuric acid Chemical compound OS(=O)(=O)OS(O)(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000005224 forefinger Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明は、N−アシルトリプタミンを含有する組成物、具体的には、しみ、吹き出物、創傷、火傷、ひび割れ、痔、筋肉痛、肩こり、腰痛、関節痛、打撲痛、二日酔いを予防又は改善するための組成物に関するものである。 The present invention prevents or ameliorates a composition containing N-acyltryptamine, specifically, spots, pimples, wounds, burns, cracks, wrinkles, muscle pain, stiff shoulders, back pain, joint pain, bruise pain, hangover It is related with the composition for.
高齢化社会に移行しつつある現在、高齢者の生活の質(QOL)を高めることは、社会福祉上重要な課題である。年齢を重ねるに従い、皮膚は衰えて、加齢皮膚には、深い「しみ」や固くなった吹き出物が形成されて、顔や手、体に現れる。若者向けの「しみ」や吹き出物を対象とした化粧品は多種、多数売られているが、高齢者は対象とされていない。加齢により、傷や火傷、ひび割れの治りや、筋肉痛、肩こり、腰痛、関節痛、打撲痛、二日酔いなどの治る速度も、遅くなっている。この衰えた体の新陳代謝能力を高めることができれば、前述の障害を改善でき、高齢者のQOLを高め、肉体的にも精神的にも、幸せを感じさせることができる。 As we are shifting to an aging society, raising the quality of life (QOL) of the elderly is an important social welfare issue. As the age increases, the skin fades, and in the aging skin, deep “stains” and hardened pimples are formed and appear on the face, hands, and body. Many kinds of “spots” for young people and cosmetics for breakouts are sold, but the elderly are not. With age, healing of wounds, burns, cracks, muscle pain, stiff shoulders, low back pain, joint pain, bruise pain, hangover, etc. has also slowed down. If the metabolic capacity of this weak body can be increased, the above-mentioned obstacles can be improved, the QOL of the elderly can be increased, and happiness can be felt physically and mentally.
N−アシルトリプタミンについては、抗鬱・抗ストレス作用について(特許文献1)、勃起障害治療及び育毛・増毛作用について(特許文献2)、メラトニン拮抗作用について(特許文献3)、それぞれ報告されているが、N−アシルトリプタミンが、しみ、吹き出物、創傷、火傷、痔、筋肉痛、肩こり、腰痛、関節痛、打撲痛、二日酔いの予防又は改善作用を有することは知られていない。 N-acyltryptamine has been reported for antidepressant / anti-stress action (Patent Document 1), erectile dysfunction treatment and hair growth / hair growth action (Patent Document 2), and melatonin antagonism (Patent Document 3). However, it is not known that N-acyltryptamine has an effect of preventing or improving stains, pimples, wounds, burns, hemorrhoids, muscle pain, stiff shoulders, back pain, joint pain, bruise pain, and hangover.
N−アシルトリプタミンは、バンレイシ属(Annona)に属する植物の種子成分として単離構造決定された天然物である(非特許文献1及び非特許文献2)。これらの植物は、中央アメリカ、エジプト、インド、東南アジア諸国で栽培され、ギュウシンリ(Annona reticulata)、チェリモア(Annona cherimola)、イランイラン(Cananga odorata)などがこの属に属する。カカオ(Theobroma cacao)にも、N−アシルトリプタミン誘導体は含まれている。これらの果実は生食の他、ジャムやママレード、アイスクリームなどに加工されて食されている。 N-acyltryptamine is a natural product whose isolated structure has been determined as a seed component of a plant belonging to the genus Annona (Non-Patent Document 1 and Non-Patent Document 2). These plants are cultivated in Central America, Egypt, India, and Southeast Asian countries, and the genus includes Annona reticulata, Annona cherimola, and Ylang-ylang (Cananga odorata). Cocoa (Theobroma cacao) also contains N-acyltryptamine derivatives. In addition to raw food, these fruits are processed into jams, mamalades, and ice cream.
N−アシルトリプタミンに構造上類似する化合物として、脳の松果腺から分泌されるホルモンであるメラトニン(N−アセチル−5−メトキシトリプタミン)、モノアミン神経伝達物質であるセロトニン(5−ヒドロキシトリプタミン)が知られており、例えば、メラトニンについては、皮膚老化の防御作用について(特許文献4)、しわ防止作用について(特許文献5)、それぞれ報告されているが、例えば、特許文献3においてN−アシルトリプタミンのメラトニン拮抗作用が報告されているように、トリプタミンの5位のメトキシ基又は水酸基の有無により、生理活性は大きく異なり、メラトニンの作用から5位にメトキシ基を有しないN−アシルトリプタミンの生理活性を予測することは困難である。 As compounds structurally similar to N-acyltryptamine, melatonin (N-acetyl-5-methoxytryptamine), a hormone secreted from the pineal gland of the brain, and serotonin (5-hydroxytryptamine), a monoamine neurotransmitter For example, with regard to melatonin, a protective action against skin aging (Patent Document 4) and an anti-wrinkle action (Patent Document 5) have been reported, respectively. For example, in Patent Document 3, N-acyltryptamine is reported. As reported for melatonin antagonism, the physiological activity differs greatly depending on the presence or absence of the methoxy group or hydroxyl group at the 5-position of tryptamine, and the physiological activity of N-acyltryptamine having no methoxy group at the 5-position from the action of melatonin Is difficult to predict.
また、骨粗鬆症は、骨を作る骨芽細胞の働きが弱まり、破骨細胞の働きが強くなることにより発症するが、メラトニンは骨芽細胞の働きを弱めることが報告されており(非特許文献3)、高齢者がメラトニンを服用すれば、骨粗鬆症を引き起こす可能性が高くなるおそれがある。 In addition, osteoporosis develops when the function of osteoblasts that make bones is weakened and the function of osteoclasts is strengthened, but melatonin has been reported to weaken the function of osteoblasts (Non-patent Document 3). ) If older people take melatonin, there is a risk that osteoporosis is likely to occur.
本発明は、安全性の高いしみ、吹き出物、筋肉痛、肩こり、腰痛、関節痛、打撲痛、創傷、火傷、ひび割れ、痔、二日酔いの予防又は改善用組成物を提供することを課題とする。 An object of the present invention is to provide a composition for preventing or improving highly safe spots, pimples, muscle pain, stiff shoulders, back pain, joint pain, bruise pain, wounds, burns, cracks, wrinkles, and hangovers.
本発明者らは、N−アシルトリプタミンが、α2受容体を阻止して男性器及び皮膚血管を拡張する作用を持つことを見出し、勃起不能治療薬や頭髪の育毛等への応用に関する特許を所有している(特許文献2)。 The present inventors have found that N-acyltryptamine has an action of blocking the α 2 receptor and dilating male organs and skin blood vessels, and has been granted a patent relating to the application to a drug for preventing erectile dysfunction and hair growth of the hair. Owned (Patent Document 2).
前記特許の展開を図るため、臨床試験を行っていたところ、N−アシルトリプタミンの新規な作用を見出した。即ち、これらの化合物は、血管拡張作用を原因として、各組織の新陳代謝機能を高め、古い皮膚の細胞が新しい細胞に置き換わる速度が速められて、顔や腕にできるしみや、皮膚にできる吹き出物が、垢として落ちていく。その結果、しみや吹き出物の治療に、著効を示すことを見出した。更に、傷、火傷、痔、手足のひび割れの修復能力も促進されることが判った。肝臓の機能も昂進され、疲労物質の代謝やアルコールの代謝速度が促進されて、運動後の筋肉痛、肩こり、腰痛、関節痛、打撲痛及び二日酔いの治療にも著効を示した。 A clinical trial was conducted to develop the patent, and a novel action of N-acyltryptamine was found. That is, these compounds increase the metabolic function of each tissue due to the vasodilatory effect, and the speed at which old skin cells are replaced with new cells is increased, resulting in spots on the face and arms and skin breakouts. , Will fall as dirt. As a result, it was found that it was effective in treating spots and breakouts. Furthermore, it was found that the ability to repair wounds, burns, wrinkles and cracks in the limbs was also promoted. The liver function was also promoted, the metabolism of fatigue substances and alcohol was accelerated, and it was also effective in treating muscle pain, stiff shoulders, low back pain, joint pain, bruise pain and hangover after exercise.
本発明の要旨は、以下のとおりである。
(1)次式(I):
The gist of the present invention is as follows.
(1) The following formula (I):
(式中、Rは炭素数2〜29の飽和脂肪族炭化水素基を表す。)
で示されるN−アシルトリプタミン、又はその薬学的に許容される塩、水和物もしくは溶媒和物を含有するしみ及び/又は吹き出物の予防及び/又は改善用組成物。
(2)前記式(I)で示されるN−アシルトリプタミン、又はその薬学的に許容される塩、水和物もしくは溶媒和物を含有する筋肉痛、肩こり、腰痛、関節痛及び/又は打撲痛の予防及び/又は改善用組成物。
(3)前記式(I)で示されるN−アシルトリプタミン、又はその薬学的に許容される塩、水和物もしくは溶媒和物を含有する創傷、火傷、ひび割れ及び/又は痔の予防及び/又は改善用組成物。
(4)前記式(I)で示されるN−アシルトリプタミン、又はその薬学的に許容される塩、水和物もしくは溶媒和物を含有する二日酔いの予防及び/又は改善用組成物。
(5)前記式(I)においてRが炭素数6〜17の飽和脂肪族炭化水素基である前記(1)〜(4)のいずれかに記載の組成物。
(In the formula, R represents a saturated aliphatic hydrocarbon group having 2 to 29 carbon atoms.)
A composition for the prevention and / or improvement of stains and / or pimples containing N-acyltryptamine represented by the formula (I) or a pharmaceutically acceptable salt, hydrate or solvate thereof.
(2) Muscle pain, stiff shoulders, low back pain, joint pain and / or bruise pain containing N-acyltryptamine represented by the above formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof. A composition for preventing and / or improving the above.
(3) Prevention and / or prevention of wounds, burns, cracks and / or wrinkles containing N-acyltryptamine represented by the above formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof. Composition for improvement.
(4) A composition for preventing and / or improving hangover containing the N-acyltryptamine represented by the formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof.
(5) The composition according to any one of (1) to (4), wherein R is a saturated aliphatic hydrocarbon group having 6 to 17 carbon atoms in the formula (I).
本発明によれば、安全性の高いしみ、吹き出物、筋肉痛、肩こり、腰痛、関節痛、打撲痛、創傷、火傷、ひび割れ、痔、二日酔いの予防又は改善用組成物を提供することができる。本発明は、高齢者の生活の質(QOL)を高める組成物を提供することを主な目的とするが、当然のことながら、本発明の組成物は若者にも適用できる。 According to the present invention, it is possible to provide a composition for preventing or improving highly safe spots, pimples, muscle pain, stiff shoulders, back pain, joint pain, bruise pain, wounds, burns, cracks, wrinkles, and hangovers. The main object of the present invention is to provide a composition that enhances the quality of life (QOL) of the elderly, but it should be understood that the composition of the present invention can also be applied to young people.
前記式(I)においてRで表される炭素数2〜29の飽和脂肪族炭化水素基としては、例えば、エチル基、プロピル基、イソプロピル基、ブチル基、イソブチル基、sec−ブチル基、tert−ブチル基、ペンチル基、イソペンチル基、ヘキシル基、ヘプチル基、オクチル基、ノニル基、デシル基、ウンデシル基、ドデシル基、トリデシル基、テトラデシル基、ペンタデシル基、ヘキサデシル基、ヘプタデシル基、オクタデシル基、ノナデシル基、イコシル基、ヘンイコシル基、ドコシル基等の直鎖状又は分岐状のC2−29−アルキル基等の炭素数2〜29の飽和脂肪族炭化水素基が挙げられる。 Examples of the saturated aliphatic hydrocarbon group having 2 to 29 carbon atoms represented by R in the formula (I) include an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, and a tert-butyl group. Butyl, pentyl, isopentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl And a saturated aliphatic hydrocarbon group having 2 to 29 carbon atoms such as a linear or branched C2-29-alkyl group such as icosyl group, henicosyl group, and docosyl group.
前記炭素数2〜29の飽和脂肪族炭化水素基としては、炭素数6〜17の飽和脂肪族炭化水素基が好ましい。特に、前記式(I)においてRで表される炭素数2〜29の飽和脂肪族炭化水素基が炭素数8のオクチル基であるN−ノナノイルトリプタミンが最も強い作用を示し、好適に実施できる。 The saturated aliphatic hydrocarbon group having 2 to 29 carbon atoms is preferably a saturated aliphatic hydrocarbon group having 6 to 17 carbon atoms. In particular, N-nonanoyltryptamine in which the saturated aliphatic hydrocarbon group having 2 to 29 carbon atoms represented by R in the formula (I) is an octyl group having 8 carbon atoms exhibits the strongest action and can be suitably implemented. .
前記式(I)で示される化合物の薬学的に許容される塩としては、例えば、塩酸、硫酸、リン酸、臭化水素酸、ヨウ化水素酸、硝酸、ピロ硫酸、メタリン酸等の無機酸、又はクエン酸、安息香酸、酢酸、プロピオン酸、フマル酸、マレイン酸、スルホン酸(例えば、メタンスルホン酸、p−トルエンスルホン酸、ナフタレンスルホン酸)等の有機酸との塩が挙げられる。 Examples of the pharmaceutically acceptable salt of the compound represented by the formula (I) include inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid, hydroiodic acid, nitric acid, pyrosulfuric acid, and metaphosphoric acid. Or a salt with an organic acid such as citric acid, benzoic acid, acetic acid, propionic acid, fumaric acid, maleic acid, sulfonic acid (for example, methanesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid).
前記式(I)で示される化合物は、公知化合物であり、合成、又は植物からの抽出により調製することができ、例えば、トリプタミンと各種カルボン酸のハロゲン化物とを反応させるか、あるいはトリプタミンと各種カルボン酸とをカルボン酸の活性化剤共存下に反応させて合成できる(特許文献2、K. Yamada, Y. Tanaka, M. Somei, Heterocycles, 79, 635-645 (2009))。 The compound represented by the formula (I) is a known compound and can be prepared by synthesis or extraction from plants. For example, tryptamine and halides of various carboxylic acids are reacted, or tryptamine and various compounds It can be synthesized by reacting a carboxylic acid with a carboxylic acid activator (Patent Document 2, K. Yamada, Y. Tanaka, M. Somei, Heterocycles, 79, 635-645 (2009)).
また、前記式(I)で示される化合物を含む植物、バンレイシ属(Annona)植物(例えば、ギュウシンリ(Annona reticulata)、チェリモア(Annona cherimola)、バンレイシ(Annona squamosa))、イランイラン(Cananga odorata)又はカカオ(Theobroma cacao))の種子又は果実を含水エタノールで抽出した後、例えば、非特許文献1に記載の方法に従ってカラムクロマトグラフィーで精製して、N−アシルトリプタミンの混合物を得ることができる。この混合物をそのまま、本発明の組成物の有効成分として使用してもよい。 Further, a plant containing the compound represented by the formula (I), an Annona plant (for example, Annona reticulata, Annona cherimola, Annona squamosa), ylang ylang (Cananga odorata) or The seeds or fruits of cocoa (Theobroma cacao) can be extracted with water-containing ethanol and then purified by column chromatography according to the method described in Non-Patent Document 1, for example, to obtain a mixture of N-acyltryptamines. You may use this mixture as an active ingredient of the composition of this invention as it is.
N−アシルトリプタミンを天然物として含む植物の果実が、食されていることから、その安全性は証明されている。また、本発明者らは、N−ノナノイルトリプタミンについて、雄のddyマウスを用いた毒性試験を行い、そのLD50が80mg/kg以上であり(K. Yamada, Y. Tanaka, M. Somei, Heterocycles, 79, 635-645 (2008))、解剖所見にも何ら異常は認められず、N−アシルトリプタミンが安全な化合物であることを見出した。更に、中国内モンゴルで山羊のカシミアの毛の増収を目的とした実験で、N−ノナノイルトリプタミンを、一日1.0mg/50kg/dayの用量で2年半に渡って投与しても、何ら異常がなく、強い繁殖効果、及びカシミアの毛が重量比で1.2〜1.7倍に増産されることを見出した(M. Somei, Heterocycles, 75, 1021-1053 (2008))。これらの結果から、N−アシルトリプタミンの安全性が確認された。 Since the fruits of plants containing N-acyltryptamine as a natural product are eaten, their safety has been proven. In addition, the present inventors conducted a toxicity test on N-nonanoyltryptamine using male ddy mice, and had an LD 50 of 80 mg / kg or more (K. Yamada, Y. Tanaka, M. Somei, Heterocycles, 79, 635-645 (2008)), and no abnormality was observed in the anatomical findings, and N-acyltryptamine was found to be a safe compound. Furthermore, in an experiment aimed at increasing the yield of goat cashmere hair in Inner Mongolia, N-nonanoyltryptamine was administered at a dose of 1.0 mg / 50 kg / day for two and a half years. It was found that there was no abnormality, a strong reproductive effect, and the cashmere hair was increased by 1.2 to 1.7 times by weight (M. Somei, Heterocycles, 75, 1021-1053 (2008)). From these results, the safety of N-acyltryptamine was confirmed.
本発明の組成物は、前記したように安全性が高いので、単独あるいは他の医薬もしくは任意の製剤用担体、希釈剤、被覆剤等と混合し、任意の剤形にして投与できる。投与方法としては、経口、非経口、直腸経由、経皮又は他の任意の投与経路を用いることができる。経口投与する場合には、散剤、錠剤、顆粒剤、カプセル剤、経口用液体製剤等を例示でき、非経口投与する場合には、注射剤、液体製剤、軟膏剤、クリーム剤、塗布剤、貼付剤、噴射剤等を、直腸投与する場合には、坐剤、カプセル剤等を例示することができる。これらの調製方法は、それぞれ既知の方法に従うことができる。 Since the composition of the present invention has high safety as described above, the composition of the present invention can be administered alone or mixed with other pharmaceuticals or any other pharmaceutical carrier, diluent, coating agent, etc., and administered in any dosage form. As an administration method, oral, parenteral, rectal, transdermal or any other administration route can be used. For oral administration, powders, tablets, granules, capsules, oral liquid preparations, etc. can be exemplified, and for parenteral administration, injections, liquid preparations, ointments, creams, coatings, patches When suppositories, propellants and the like are administered rectally, suppositories, capsules and the like can be exemplified. Each of these preparation methods can follow a known method.
本発明の組成物は、前記したように安全性が高いので、これを各種の飲食品に配合することにより、しみ、吹き出物、創傷、火傷、手足のひび割れ、筋肉痛、肩こり、腰痛、関節痛、打撲痛、二日酔いの予防・改善作用を有する組成物を提供することができる。例えば、組成物としては、チューインガム、チョコレート、スナック等の菓子、ジュース、スポーツドリンク、清涼飲料水、牛乳、果実飲料、ココア等の飲料、アイスクリーム、ヨーグルト、ふりかけ、香辛料、健康用食品(例えば、特定保健用食品)、そのほかの食品をあげることができる。 Since the composition of the present invention is highly safe as described above, by blending it into various foods and drinks, stains, pimples, wounds, burns, limb cracks, muscle pain, stiff shoulders, back pain, joint pain It is possible to provide a composition having an effect of preventing / ameliorating bruising pain and hangover. For example, the composition includes chewing gum, chocolate, snacks and other sweets, juices, sports drinks, soft drinks, milk, fruit drinks, cocoa drinks, ice cream, yogurt, sprinkles, spices, health foods (for example, Foods for specified health use) and other foods.
本発明の組成物におけるN−アシルトリプタミンの含有量は、その剤形に応じて最適量が異なるので限定されるものではないが、一般的に製剤当りの含有量を0.001重量%〜10重量%、好ましくは0.01〜1重量%になるように調整する。 The content of N-acyltryptamine in the composition of the present invention is not limited because the optimal amount varies depending on the dosage form, but generally the content per formulation is 0.001 wt% to 10 wt%. It adjusts so that it may become weight%, Preferably 0.01-1 weight%.
成人の場合、N−アシルトリプタミンの用量は、体重1kg及び1日1回当り0.001〜10mg、好ましくは0.01〜0.1mgである。この使用量を1日1回又は数回に分けて投与することができる。 In the case of an adult, the dose of N-acyltryptamine is 0.001 to 10 mg, preferably 0.01 to 0.1 mg, per kg of body weight and once a day. This amount can be administered once a day or divided into several times.
以下に、本発明を具体的に説明するため、調製例及び実施例をあげるが、本発明はこれらに限定されるものではない。 In order to illustrate the present invention specifically, preparation examples and examples are given below, but the present invention is not limited thereto.
(調製例1)合成方法
染井らの方法(K. Yamada, Y. Tanaka, M. Somei, Heterocycles, 79, 635-645 (2009))に従いN−ノナノイルトリプタミンを合成し、以下の調製例3及び実施例に用いた。
(Preparation Example 1) Synthesis Method N-nonanoyltryptamine was synthesized according to the method of Somei et al. (K. Yamada, Y. Tanaka, M. Somei, Heterocycles, 79, 635-645 (2009)). And used in the examples.
(調製例2)植物からの抽出方法
インドネシア産バンレイシ(Annona squamosa)の果実を乾燥し、全体を粉砕した。この粉砕粉末50gに、80%エタノール水溶液を1L加え1時間加熱還流して抽出した。冷却後、抽出液を濾過して不溶物を除き、溶媒を減圧留去、乾燥して、バンレイシ果実の粗抽出物18.4gを得た。この粗抽出物からは、D. Chavez らの方法(非特許文献1)に従ってカラムクロマトグラフィーで精製して、N−アシルトリプタミンの混合物が得られた。
(Preparation Example 2) Extraction method from plant The fruit of Indonesian Anemona squamosa was dried and crushed. To 50 g of this pulverized powder, 1 L of 80% ethanol aqueous solution was added and extracted by heating under reflux for 1 hour. After cooling, the extract was filtered to remove insolubles, and the solvent was distilled off under reduced pressure and dried to obtain 18.4 g of a crude extract of bancii fruit. The crude extract was purified by column chromatography according to the method of D. Chavez et al. (Non-patent Document 1) to obtain a mixture of N-acyltryptamines.
(調製例3)組成物の調製
散剤:ガラクトース又は乳糖を希釈剤として、N−ノナノイルトリプタミンを0.5重量%となるように混和して製した。
液剤:N−ノナノイルトリプタミン4gをエタノール4Lに溶解し、精製水1Lを加えて、0.8%エタノール水溶液を製した。
クリーム剤:ワセリン、グリセリン、馬鈴薯澱粉の7:1.5:1.5の混合物に、N−ノナノイルトリプタミンを0.5重量%となるように混和して製した。
(Preparation example 3) Preparation of composition Powder: N-nonanoyltryptamine was mixed to 0.5% by weight using galactose or lactose as a diluent.
Solution: 4 g of N-nonanoyltryptamine was dissolved in 4 L of ethanol, and 1 L of purified water was added to prepare a 0.8% aqueous ethanol solution.
N-nonanoyltryptamine was mixed in a 7: 1.5: 1.5 mixture of cream: petrolatum, glycerin and potato starch so as to be 0.5% by weight.
本発明の組成物は、N−アシルトリプタミンを必須成分とするが、必要に応じて、本発明の効果を損なわない範囲内で、食品、化粧品、医薬部外品、医薬品等に一般的に用いられる各種成分、例えばグリチルレチン酸、ホルモン剤、ビタミン剤、非イオン界面活性剤、カチオン界面活性剤、アニオン界面活性剤、半極性界面活性剤、保温剤、増粘剤、防腐剤、酸化防止剤、香料、色剤、各種植物の抽出エキス等を配合することができる。 The composition of the present invention contains N-acyltryptamine as an essential component, but is generally used for foods, cosmetics, quasi-drugs, pharmaceuticals, etc., as long as the effects of the present invention are not impaired. Various ingredients such as glycyrrhetinic acid, hormones, vitamins, nonionic surfactants, cationic surfactants, anionic surfactants, semipolar surfactants, heat retention agents, thickeners, preservatives, antioxidants, A fragrance | flavor, a coloring agent, the extract of various plants, etc. can be mix | blended.
(実施例1)「しみ」の治療
治療患者:65歳、健康男子。
治療場所:患者の自宅。
治療期間:2007年9月12日から10月31日(50日間)。
患部状況:加齢により、自然に形成された右腕外側の黒い「しみ」3カ所。
使用組成物:調製例3の液剤及びクリーム剤。
治療方法:調製例3の液剤を「しみ」に塗布し、乾いた後に調製例3のクリーム剤を擦り込んだ。12時間おきに、1日2回塗布と擦り込みを行った。
結 果:50日間という短い期間で、図1で見られる3個の「しみ」が、図2のように薄くなり、下側の一個は完全に消失した。その結果、肌がきれいになった。
(Example 1) Treatment and treatment of "stain": 65 years old, healthy male.
Treatment location: Patient's home.
Treatment period: September 12 to October 31, 2007 (50 days).
Situation of the affected area: 3 black “stains” on the outside of the right arm that were naturally formed by aging.
Composition used: solution and cream of Preparation Example 3.
Treatment Method: The solution of Preparation Example 3 was applied to “Blots”, dried, and then rubbed with the cream of Preparation Example 3. Application and rubbing were performed twice a day every 12 hours.
Results: In a short period of 50 days, the three “stains” seen in FIG. 1 became thinner as shown in FIG. 2, and the lower one disappeared completely. As a result, the skin became clean.
(実施例2)「しみ」及び固い「つらら状の吹き出物」の治療
治療患者:59歳、健康女子。
治療場所:患者の自宅。
治療期間:2007年10月1日から2008年9月30日(1年間)。
患部の状況:右頬及び左頬上の直径3cmの黒い大きな「しみ」が、加齢により自然に形成されていた。また、両目の瞼下、首に多数の「つらら状の吹き出物」が生成している。
使用組成物:調製例3の液剤及びクリーム剤。
治療方法:調製例3の液剤を、「しみ」及び首にある「つらら状の吹き出物」に塗布した。液が乾いた後に、調製例3のクリーム剤を擦り込んだ。12時間おきに、1日2回塗布と擦り込みを行った。
結 果:1ヶ月で、「つらら状の吹き出物」の数が減少し、また「しみ」の色が浅くなった。3ヶ月で吹き出物の全てが、消えてなくなった。右頬上の「しみ」は、薄くなったが、左頬上の「しみ」は、まだ濃かった。半年後、右頬上の「しみ」は、目立たなくなり、左頬上の「しみ」は、薄くなった。1年後、左頬上の「しみ」は、ほとんどなくなった。左頬上の「しみ」は、まだ残っているが、極めて薄くなった。その結果、肌がきれいになった。
(Example 2) Treatment and treatment of "stain" and hard "icicle pimple": 59 years old, healthy girl.
Treatment location: Patient's home.
Treatment period: October 1, 2007 to September 30, 2008 (one year).
Situation of affected area: Black large “stains” having a diameter of 3 cm on the right cheek and the left cheek were naturally formed by aging. In addition, a large number of “icicle-shaped breakouts” are generated on the neck and neck of both eyes.
Composition used: solution and cream of Preparation Example 3.
Treatment Method: The solution of Preparation Example 3 was applied to “stain” and “icicle pimple” on the neck. After the liquid dried, the cream of Preparation Example 3 was rubbed. Application and rubbing were performed twice a day every 12 hours.
Results: In one month, the number of “icicle-like breakouts” decreased and the color of “stains” became shallower. In 3 months, all of the breakout disappeared. The “stain” on the right cheek became thinner, but the “stain” on the left cheek was still dark. Half a year later, the “stain” on the right cheek became inconspicuous and the “stain” on the left cheek became thinner. One year later, there was almost no “stain” on the left cheek. The “stain” on the left cheek still remains, but has become very thin. As a result, the skin became clean.
(実施例3)創傷治療
治療患者:65歳、健康男子。
治療場所:患者の自宅。
治療期間:2007年8月19日(受傷)から8月26日。
受傷状況:戯れていた飼い猫に右腕を激しく引っかかれ、多数の傷を負った。
治療薬物:調製例3のクリーム剤。
治療方法:調製例3のクリーム剤を受傷直後に塗布した。以後、12時間おきに塗布した。
結 果:受傷直後塗布により、出血、痛みが止まる(図3(右腕手首に近い部分)、図4(右腕中央部))。1日後、傷口は、通常見られる血液凝固の「かさぶた」がなく、代わりに薄い皮膜ができて傷口が塞がっていた。「かさぶた」だと、風呂に入り、その上を洗うと傷口が開くが、傷口は開かず、洗うことができた。修復速度が早く、1週間で完治した(図5(右腕手首に近い部分)、図6(右腕中央部))。
(Example 3) Wound treatment patient: 65 years old, healthy male.
Treatment location: Patient's home.
Treatment period: August 19, 2007 (injured) to August 26.
Injury situation: A playful domestic cat was violently pulled by his right arm and injured numerous wounds.
Therapeutic drug: Cream of Preparation Example 3.
Treatment method: The cream of Preparation Example 3 was applied immediately after injury. Thereafter, it was applied every 12 hours.
Results: Immediately after being injured, bleeding and pain cease (Fig. 3 (portion near the right arm wrist), Fig. 4 (central portion of the right arm)). One day later, the wound did not have the blood clotting “scab” normally seen, but instead a thin film was formed to close the wound. With the scab, when I took a bath and washed it, the wound opened, but the wound did not open and I could wash it. The repair speed was fast and it was completely cured in one week (FIG. 5 (portion close to the right arm wrist), FIG. 6 (center portion of the right arm)).
(実施例4)手指のひび割れ治療
治療患者:60歳、健康主婦。
治療場所:患者の自宅。
治療期間:2008年12月20日から1月31日。
受傷状況:冬の炊事、洗濯等の水を扱うことに加え、寒風にさらされることにより、手の親指、人差し指、中指の先端部が乾燥して、大きなひび割れを生じていた。出血、痛みも伴って、裁縫などができなくなってしまった。
治療薬物:調製例3のクリーム剤。
治療方法:調製例3のクリーム剤を洗濯後、炊事後、及び就寝前に患部に擦り込んだ。
結 果:クリームを擦り込み、30分後には痛みが止まり、かさかさの皮膚が柔らかくなった。1日後、傷口も塞がり始めた。作業をしても、痛みをこらえる程ではなくなった。修復速度が早く、約40日後には、ほぼ完治した。
(Example 4) Treatment patient for cracking of fingers: 60 years old, healthy housewife.
Treatment location: Patient's home.
Treatment period: December 20, 2008 to January 31.
Injury situation: In addition to handling water for cooking and washing in winter, the tip of the thumb, forefinger, and middle finger dried out due to exposure to cold winds, resulting in large cracks. He was unable to sew with bleeding and pain.
Therapeutic drug: Cream of Preparation Example 3.
Treatment method: The cream of Preparation Example 3 was rubbed into the affected area after washing, after cooking, and before going to bed.
Result: The cream was rubbed, and after 30 minutes, the pain stopped and the bulky skin became soft. One day later, the wound started to close. Even after working, it wasn't painful enough. The repair speed was fast, and it was almost completely cured after about 40 days.
(実施例5)天ぷら火傷治療
治療患者:58歳、健康主婦。
治療場所:患者の自宅。
治療期間:2008年5月2日(受傷)から5月10日。
受傷状況:天ぷらを揚げていたところ、突然油がはねて、顔面に火傷を負った。すぐに水で冷やしたが、火ぶくれになった。
治療薬物:調製例3の液剤。
治療方法:調製例3の液剤を受傷直後患部に塗布した。痛みはきつかった。以後、12時間おきに塗布した。
結 果:塗布により、ひどい痛みが徐々に治まり、普通に就寝もできた。1日後、腫れも退き、火ぶくれによる傷口が塞がった。修復速度が早く、9日でほぼ完治した。
(Example 5) Tempura burn treatment patient: 58 years old, healthy housewife.
Treatment location: Patient's home.
Treatment period: May 2, 2008 (injury) to May 10th.
Injury situation: When fried tempura, the oil suddenly splashed and burned the face. Immediately cooled with water, but started to burn.
Therapeutic drug: Solution of Preparation Example 3.
Treatment method: The solution of Preparation Example 3 was applied to the affected area immediately after injury. The pain was tight. Thereafter, it was applied every 12 hours.
Result: After application, the severe pain gradually subsided, and I was able to go to bed normally. One day later, the swelling also ceased and the wound from the blister was closed. The repair speed was fast, and it was almost completely cured in 9 days.
(実施例6)痔の治療
治療患者:64歳の健康男子。
治療場所:患者の自宅。
治療期間:2006年12月9日から2007年6月8日(半年間)。
状 況:長年の経過で、切れ痔となった。排便時には痛みと共に、血液が吹き出て人にはいえぬ苦しみを耐えていた。
治療薬物:調製例3のクリーム剤。
治療方法:12時間おきに1日2回、患部に擦り込んだ。
結 果:日常生活上感じていた痛みが、1時間後には和らいだ。3日後には、患部の皮膚が柔らかくなり、傷口が塞がった。1ヶ月後には、排便時の出血も痛みもほとんど感じなくなった。3ヶ月後、痔であったことを忘れるほど、気にならなくなり、半年でほぼ完治した。
(Example 6) Acupuncture treatment patient: a 64-year-old healthy boy.
Treatment location: Patient's home.
Treatment period: December 9, 2006 to June 8, 2007 (half year).
Situation: Over the years, it became severe. At the time of defecation, with the pain, blood was blown out and the suffering that could not be said to humans was endured.
Therapeutic drug: Cream of Preparation Example 3.
Treatment method: Rubbed into the affected area twice a day every 12 hours.
Result: The pain I felt in my daily life eased after 1 hour. Three days later, the affected skin became soft and the wound was closed. After one month, there was almost no bleeding or pain during defecation. Three months later, the more I forgot that I was addicted, the less I was bothered.
(実施例7)筋肉痛、肩こり、腰痛、関節痛及び打撲痛の解消
治療患者:63歳、健康男子。
治療場所:患者の自宅。
治療期間:2005年11月3日から11月5日(3日間)。
状 況:朝の野球の試合でピッチャーとして、約100球を投げた。また打球があたり、左足に打撲を受けた。試合直後の12時頃から筋肉痛、肩こり、腰痛、関節痛及び打撲痛が出始め、痛みと、だるさで膝が笑い、体の自由が利かなくなった。
治療薬物:組成物調製欄に記した散剤及び液剤。
治療方法:調製例3の散剤をN−ノナノイルトリプタミン1mg相当量1日2回、12時間おきに服用した。また、筋肉痛、肩こり、腰痛、関節痛及び打撲部に調製例3の液剤を8時間おきに1日3回塗布した。
結 果:服用及び塗布後、2時間で、筋肉痛、肩こり、腰痛、関節痛及び打撲痛はひどいが、手足の自由がきき始め、歩けるようになった。5時間後の夕方には、だるさが解消した。翌日、12時には筋肉痛、肩こり、腰痛及び関節痛は若い頃と同じ程度になった。時間の経過と共に、筋肉痛、肩こり、腰痛、関節痛及び打撲痛が、ぐんぐんと消えていくのを、本人が感じていた。翌3日目には、ほとんど筋肉痛、肩こり、腰痛、関節痛及び打撲痛は解消し、普段通りの生活に戻った。
(Example 7) Muscular pain, stiff shoulders, low back pain, joint pain, and bruise pain treatment patient: 63 years old, healthy male.
Treatment location: Patient's home.
Treatment period: November 3 to November 5, 2005 (3 days).
Situation: Throwing about 100 balls as a pitcher in a baseball game in the morning. The ball hit and the left foot was bruised. Muscle pain, stiff shoulders, low back pain, joint pain and bruise started to appear around 12:00 immediately after the game, and the knees laughed with pain and dullness, and freedom of the body was lost.
Therapeutic drugs: powders and solutions as described in the composition preparation column.
Treatment method: The powder of Preparation Example 3 was taken twice a day, equivalent to 1 mg of N-nonanoyltryptamine, every 12 hours. In addition, the liquid preparation of Preparation Example 3 was applied to myalgia, stiff shoulders, low back pain, joint pain and bruised area 3 times a day every 8 hours.
Results: Two hours after taking and application, muscle pain, stiff shoulders, low back pain, joint pain and bruise pain were severe, but the freedom of limbs began to come and I was able to walk. The dullness disappeared in the evening after 5 hours. The next day, at 12 o'clock, my sore muscles, stiff shoulders, low back pain and joint pain were the same as when I was young. Over time, he felt that my sore muscles, stiff shoulders, low back pain, joint pain and bruise disappeared. On the next day, almost all my sore muscles, stiff shoulders, low back pain, joint pain and bruise were resolved and I returned to my normal life.
以後、スポーツや筋肉労働を始める1時間前に、前述の散剤を服用することにより、作業後の筋肉痛、肩こり、腰痛、関節痛、だるさを、ほとんど感じなくなった。 After that, by taking the above-mentioned powder one hour before starting sports and muscular work, I almost felt no muscle pain, stiff shoulders, low back pain, joint pain, and dullness after work.
(実施例8)二日酔いの治療
治療患者:36歳及び40歳の健康男子二人。
治療場所:中国ゴビ砂漠植樹旅行先。
治療期間:2009年5月15日。
状 況:北京における前夜の歓迎会で、白酒(アルコール濃度、55%)の乾杯を重ねて、ダウンした。翌朝、顔色は蒼白、目もうつろで、気持ちが悪く、食欲は全くなかった。団体旅行の計画遂行に、支障を来す事態なので無理矢理目を覚まさせた。
治療薬物:調製例3の散剤。
治療方法:N−ノナノイルトリプタミン1mg相当量の前述の散剤を一回服用した。
結 果:二人とも、ほぼ同じ経過を辿った。服用1時間後、気持ち悪さが軽くなり、飛行機に搭乗する意欲が湧いた。約2時間のフライト中、機内で眠った。時間の経過と共に顔の血色がよくなり、快く眠っている様子であった。服用3時間後、目的地の飛行場に到着した時には、二人とも気分が回復した。時間の経過と共にどんどん回復して、その後の上下に激しく揺すられる2時間の車の移動でも、何ら支障がなかった。服用5時間後、食欲が復活、腹が減ったと食事を取り、砂漠における植樹の重労働作業にも元気に参加できた。
(Example 8) Treatment and treatment for hangover: Two healthy boys, 36 and 40 years old.
Treatment location: China Gobi desert tree planting travel destination.
Treatment period: May 15, 2009.
Situation: At the welcome party the night before in Beijing, he went down with a toast of white liquor (alcohol concentration, 55%). The next morning, the complexion was pale, the eyes were gloomy, they felt uncomfortable and had no appetite. I was awakened by force because it would be a hindrance to the group travel plan.
Therapeutic drug: Powder of Preparation Example 3.
Treatment method: The above-mentioned powder equivalent to 1 mg of N-nonanoyltryptamine was taken once.
Result: Both of them followed the same process. One hour after taking it, my feelings of sensation lightened and I was motivated to board the plane. I slept on board for about two hours. The color of the face improved over time, and she seemed to sleep comfortably. When they arrived at the destination airfield 3 hours after taking them, both of them recovered. There was no problem in moving the car for 2 hours, which gradually recovered as time passed and was shaken violently up and down. Five hours after taking it, when the appetite revived and he became hungry, he took a meal and was able to participate in the hard work of planting trees in the desert.
Claims (3)
で示されるN−アシルトリプタミン、又はその薬学的に許容される塩、水和物もしくは溶媒和物を含有する筋肉痛、肩こり、腰痛、関節痛及び/又は打撲痛の予防及び/又は改善用組成物。 Formula (I):
A composition for the prevention and / or improvement of muscle pain, stiff shoulders, low back pain, joint pain and / or bruise pain, containing N-acyltryptamine represented by the formula (I) or a pharmaceutically acceptable salt, hydrate or solvate thereof object.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013202908A JP5705939B2 (en) | 2013-09-30 | 2013-09-30 | Composition containing N-acyltryptamine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013202908A JP5705939B2 (en) | 2013-09-30 | 2013-09-30 | Composition containing N-acyltryptamine |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009144286A Division JP5380170B2 (en) | 2009-06-17 | 2009-06-17 | Composition containing N-acyltryptamine |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013256538A true JP2013256538A (en) | 2013-12-26 |
JP5705939B2 JP5705939B2 (en) | 2015-04-22 |
Family
ID=49953252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013202908A Active JP5705939B2 (en) | 2013-09-30 | 2013-09-30 | Composition containing N-acyltryptamine |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5705939B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7048051B2 (en) | 2018-07-11 | 2022-04-05 | 正徳 染井 | Atopic dermatitis remedy to reduce itching |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11510804A (en) * | 1995-08-08 | 1999-09-21 | セ・エ・エム・ア・エフ | Acylated derivatives of melatonin and its analogues useful as medicaments |
JP2003137780A (en) * | 2001-11-01 | 2003-05-14 | Lotte Co Ltd | Antidepressant and antistress agent and composition containing the agent |
JP2003325134A (en) * | 2002-05-08 | 2003-11-18 | Toyo Shinyaku:Kk | Health food |
JP2008525447A (en) * | 2004-12-22 | 2008-07-17 | エイボン プロダクツ インコーポレーテッド | Composition for improving skin condition and appearance and method of use thereof |
-
2013
- 2013-09-30 JP JP2013202908A patent/JP5705939B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11510804A (en) * | 1995-08-08 | 1999-09-21 | セ・エ・エム・ア・エフ | Acylated derivatives of melatonin and its analogues useful as medicaments |
JP2003137780A (en) * | 2001-11-01 | 2003-05-14 | Lotte Co Ltd | Antidepressant and antistress agent and composition containing the agent |
JP2003325134A (en) * | 2002-05-08 | 2003-11-18 | Toyo Shinyaku:Kk | Health food |
JP2008525447A (en) * | 2004-12-22 | 2008-07-17 | エイボン プロダクツ インコーポレーテッド | Composition for improving skin condition and appearance and method of use thereof |
Also Published As
Publication number | Publication date |
---|---|
JP5705939B2 (en) | 2015-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2793905B1 (en) | Ellagitannins rich extracts composition in sexual wellness | |
JP2010530841A (en) | Selective serotonin reuptake inhibiting composition and method | |
JP2022009308A (en) | Composition for ameliorating climacteric symptoms or osteoporosis | |
TW201219360A (en) | Heat shock protein expression inducer | |
KR20240004452A (en) | 1-Methylxanthine-based bioactive compositions and methods of using the same | |
JP2000191542A (en) | Preventive/therapeutic agent for osteoporosis | |
JP5705940B2 (en) | Composition containing N-acyltryptamine | |
JP5705939B2 (en) | Composition containing N-acyltryptamine | |
JP7125516B2 (en) | Growth-promoting food composition and growth-promoting pharmaceutical composition containing Canamugra extract or Pulverized Canamugra as an active ingredient | |
JP5380170B2 (en) | Composition containing N-acyltryptamine | |
KR100456281B1 (en) | Therapeutic agent for improving bladder function or treating urinary disturbance and food and drink for improving bladder function or treating urinary disturbance | |
KR20180002158A (en) | A composition for removing hangover comprising an herb extract including ginseng | |
RU2016135793A (en) | Compositions and methods of inhibiting triglyceride synthesis using a synergistic combination of botanical compounds | |
KR102275268B1 (en) | Composition for relieving menopausal symptom or osteoporosis | |
KR101808944B1 (en) | Composition for preventing and treating dysmenorrhea and premature labor comprising non-polar solvent subfraction from Zingiber officinale extract | |
JP6787944B2 (en) | Muscle fatigue recovery agent | |
KR101706649B1 (en) | Composition for inhibiting toxicity of bisphenol A comprising glucosinolate | |
KR101610894B1 (en) | Taste-masked granules containing vitamin C | |
CN106420483A (en) | Skin-clearing blackhead dissolving solution | |
US10406190B2 (en) | Composition and method for treating menopausal symptoms | |
KR102347819B1 (en) | Composition for relieving menopausal symptom or osteoporosis | |
KR20010086473A (en) | Composition of essential oil having an inhibitary activity on the formation of leucotriens | |
KR102496751B1 (en) | Fruits of Acanthopanax sessiliflorus extract including obesity prevention functional ingredients and method for manufacturing it | |
CN107397837A (en) | A kind of loose skin tea oil liquid for curing scald and burn and usage food decoction chemical product physiotherapy decoction | |
EP3449736B1 (en) | Composition for relieving menopausal symptom or osteoporosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130930 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141021 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141202 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150210 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150225 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5705939 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |